<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202837</url>
  </required_header>
  <id_info>
    <org_study_id>B1801378</org_study_id>
    <secondary_id>B1801378</secondary_id>
    <secondary_id>REACH-RA</secondary_id>
    <nct_id>NCT02202837</nct_id>
  </id_info>
  <brief_title>Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice</brief_title>
  <acronym>REACH RA</acronym>
  <official_title>Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Rheumatoid Arthritis Patients Treated With Etanercept (Enbrel (Registered))</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Defining Which Remission Criterion at Month 6 Predicts Remission at Month 12 in a Real Life
      Clinical Practice, in a Cohort of Rheumatoid Arthritis Patients Treated with Etanercept
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The analysis of the primary endpoint will be based on a logistic regression defining the
      dependent variable as the remission at Month 12 and the 5 independent variables as CDAI,
      SDAI, DAS28, DAS28 and Ultrasound, and EULAR Boolean definition for clinical practice and
      clinical studies.

      This analysis will be conducted in each arm of the study as well as after a pooling of both
      patient groups.

      In this context it seems reasonable to ensure the completion of the study by a total
      approximate number of 100 patients (approximately 50 patients per arm). In order to ensure 50
      completers in each arm, 70 patients will be recruited at baseline, taking into account a drop
      out rate of 30% over 1 year period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 12, 2014</start_date>
  <completion_date type="Actual">April 24, 2017</completion_date>
  <primary_completion_date type="Actual">April 24, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with Disease Activity Score Based on 28-joints Count (DAS28) &lt;2.6 at month 6 maintained till month 12</measure>
    <time_frame>12 months</time_frame>
    <description>DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 &gt;3.2 to 5.1 = moderate to high disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with Clinical Disease Activity Index (CDAI) ≤ 2.8 at month 6 maintained till month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical Disease Activity Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with Simplified Disease Activity Index (SDAI) ≤ 3.3 at month 6 maintained till month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Simplified Disease Activity Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with no signs of ultrasound synovitis at month 6 (ultrasound remission) maintained till month 12</measure>
    <time_frame>12 months</time_frame>
    <description>US 7 Joint Score system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with Clinical Disease Activity Index (CDAI) Boolean definition (SJC&lt;1, TJC&lt;1 and PtGA&lt;1) at month 6 maintained till month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical Disease Activity Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with Simplified Disease Activity Index (SDAI) Boolean definition (SJC&lt;1, TJC&lt;1 and PtGA&lt;1, CRP &lt;1) at month 6 maintained till month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Simplified Disease Activity Index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Disease Activity Score Based on 28-joints Count (DAS28) &lt; 2.6</measure>
    <time_frame>6 months</time_frame>
    <description>DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 &gt;3.2 to 5.1 = moderate to high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Clinical Disease Activity Index (CDAI) ≤ 2.8</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical Disease Activity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Simplified Disease Activity Index (SDAI) ≤ 3.3</measure>
    <time_frame>6 months</time_frame>
    <description>Simplified Disease Activity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with no signs of ultrasound synovitis (ultrasound remission)</measure>
    <time_frame>6 months</time_frame>
    <description>US 7 Joint score system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Clinical Disease Activity Index (CDAI) Boolean definition (SJC&lt;1, TJC&lt;1 and PtGA&lt;1)</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical Disease Activity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Simplified Disease Activity Index (SDAI) Boolean definition (SJC&lt;1, TJC&lt;1 and PtGA&lt;1, CRP &lt;1)</measure>
    <time_frame>6 months</time_frame>
    <description>Simplified Disease Activity Index</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">135</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Etanercept First</arm_group_label>
    <description>Adult patients with RA who receive etanercept as first biologic, according to prevailing Belgian reimbursement criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept second</arm_group_label>
    <description>Adult patients who receive etanercept as second biologic, according to prevailing Belgian reimbursement criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>etanercept 1 x 50 mg/week or 2 x 25mg/week</description>
    <arm_group_label>Etanercept First</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>etanercept 1 x 50 mg/week or 2 x 25mg/week</description>
    <arm_group_label>Etanercept second</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients presenting with moderate-to-severe RA in daily clinical practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with active RA who start treatment with etanercept according to the
             prevailing reimbursement criteria and dosing in line with the SmPC.

               1. First cohort: Etanercept is the first biological product prescribed.

               2. Second cohort: Etanercept is the second biological product prescribed.

          2. Capable of understanding and willing to provide signed and dated written, voluntary
             informed consent before any protocol-specific procedures are performed.

          3. Eighteen (18) years of age or older at time of consent.

        Exclusion Criteria:

        1. History of or current psychiatric illness that would interfere with the subject's
        ability to comply with protocol requirements or to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algemeen Stedelijk Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>B-9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>B-9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>B-9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lucas ZH</name>
      <address>
        <city>Assebroeck</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Lucas Ziekenhuis</name>
      <address>
        <city>Assebroek</city>
        <zip>B-8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHIREC</name>
      <address>
        <city>Brussels</city>
        <zip>1040</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Champion</city>
        <zip>B-5020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedical Research Institute/ Department of Rheumatology</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Rheumatology</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologie Associatie</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Genk</city>
        <zip>B-3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHdC</name>
      <address>
        <city>Gilly</city>
        <zip>B-6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Grand-Manil</city>
        <zip>5030</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Campus Sint Maarten</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tivoli</name>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman/ Department of Rheumatology</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisastraat 18</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Pare</name>
      <address>
        <city>Mons</city>
        <zip>B-7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saintethérèse</name>
      <address>
        <city>Montigny Sur Sambre</city>
        <zip>6061</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISPPC de Charleroi</name>
      <address>
        <city>Montigny-le-tilleul</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Maenaut Kristien</name>
      <address>
        <city>Schoten</city>
        <zip>B-2900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint-Andries Ziekenhuis</name>
      <address>
        <city>Tielt</city>
        <zip>B-8700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Peltzer-Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>B-4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires UCL de Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1801378&amp;StudyName=Study%20with%20Etanercept%20focusing%20on%20remission%20and%20predictability%20of%20remission%20in%20real%20life%20clinical%20practice</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 23, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

